TSHA (STOCKS)
Taysha Gene Therapies, Inc. Common Stock
$5.967100
+0.257100 (+4.50%)
Prev close: $5.710000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Sean P. Nolan
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $1,718.42M
- Employees
- 73
- P/E (TTM)
- -15.07
- P/B (TTM)
- 7.74
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
6
Strong Buy
12
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.12 | $-0.10 | -0.0204 | -20.48% |
|
Dec 2025 (Q4)
|
$-0.08 | $-0.10 | +0.0181 | +18.45% |
|
Sep 2025 (Q3)
|
$-0.09 | $-0.09 | +0.0000 | +0.00% |
|
Jun 2025 (Q2)
|
$-0.09 | $-0.08 | -0.0075 | -9.09% |
Financial Statements
| Revenues | $7.47M |
| Nonoperating Income/Loss | $2.69M |
| Operating Expenses | $140.03M |
| Research and Development | $104.65M |
| Other Operating Expenses | $35.39M |
| Operating Income/Loss | -$132.56M |
| Income/Loss From Continuing Operations After Tax | -$129.88M |
| Income/Loss From Continuing Operations Before Tax | -$129.88M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$129.88M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$129.88M |
| Net Income/Loss Available To Common Stockholders, Basic | -$129.88M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.38 |
| Diluted Earnings Per Share | -$0.38 |
| Basic Average Shares | 1,030,467,319 |
| Diluted Average Shares | 1,030,467,319 |
| Assets | $300.35M |
| Current Assets | $282.25M |
| Noncurrent Assets | $18.10M |
| Fixed Assets | $6.45M |
| Other Non-current Assets | $11.65M |
| Liabilities | $88.41M |
| Current Liabilities | $20.10M |
| Accounts Payable | $4.56M |
| Wages | $2.99M |
| Other Current Liabilities | $12.55M |
| Noncurrent Liabilities | $68.31M |
| Equity | $211.94M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $211.94M |
| Liabilities And Equity | $300.35M |
| Net Cash Flow From Operating Activities | -$111.95M |
| Net Cash Flow From Operating Activities, Continuing | -$111.95M |
| Net Cash Flow From Investing Activities | -$3.26M |
| Net Cash Flow From Investing Activities, Continuing | -$3.26M |
| Net Cash Flow From Financing Activities | $275.35M |
| Net Cash Flow From Financing Activities, Continuing | $275.35M |
| Net Cash Flow | $160.15M |
| Net Cash Flow, Continuing | $160.15M |
| Comprehensive Income/Loss | -$126.61M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$126.61M |
| Other Comprehensive Income/Loss | $3.27M |